Strong Q2 Financial Performance: Agilent reported revenue of $1.67 billion for Q2 2025, reflecting a 6% increase year-over-year and a 5.3% growth on a core basis. EPS reached $1.31, marking a 7% growth YOY. This performance exceeded company expectations, continuing a trend of accelerating growth for four consecutive quarters.

End Market Performance and Growth Recovery: Across various segments, Agilent experienced mid to high single-digit growth in most end markets. The pharmaceuticals segment grew 6%, driven by a robust small molecule sector. However, the biopharma sector is recovering at a slower pace, only achieving low single-digit growth. The diagnostics business grew 8%, benefiting from strong pathology performance, indicating a diverse growth backdrop.

Challenges with Tariffs and Macroeconomic Factors: Agilent is facing incremental tariff costs of about $50 million in the second half of the fiscal year, on top of $10 million already absorbed in the first half. The uncertain macro environment and regulatory changes are potential risks that could impact future performance, but the company is confident in its ability to manage these challenges with proactive measures.